Premier Biomedical, Inc. (OTCMKTS:BIEI – Get Free Report) was the recipient of a significant increase in short interest in the month of September. As of September 30th, there was short interest totaling 101,775 shares. Based on an average daily volume of 26,682,366 shares, the days-to-cover ratio is currently 0.0 days.
Premier Biomedical Stock Performance
BIEI stock opened at $0.00 on Wednesday. Premier Biomedical has a 1-year low of $0.00 and a 1-year high of $0.00.
Premier Biomedical Company Profile
Premier Biomedical, Inc is a biotechnology company focused on developing therapeutic products for conditions including pain, inflammation, cancer, and substance-use disorders. The company’s work has centered on proprietary formulations and drug-delivery approaches intended to provide alternatives to conventional treatments.
Premier Biomedical has historically operated as a development-stage business, emphasizing research, product formulation, and potential commercialization rather than maintaining a broad portfolio of established commercial products.
See Also
- Five stocks we like better than Premier Biomedical
- A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?
- Could T-Mobile’s Satellite Competition Fears Create a Buying Opportunity?
- Surgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow Runway
- Tesla’s Robotaxi Lands in Paris—But Europe’s Real Fight Is Over Cheap EVs
Receive News & Ratings for Premier Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Premier Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.
